Amodiaquine+Artesunate vs. Artemether-Lumefantrine for Uncomplicated Malaria in Ghanaian Children
Status:
Unknown status
Trial end date:
2006-12-01
Target enrollment:
Participant gender:
Summary
Artemisinin combination therapies (ACT) are currently recommended for malaria treatment.
Artemether-lumefantrine(A-L) and Artesunate+amodiaquine (A+A) have been the most commonly
adopted of the recommended ACT regimens. In Ghana, A+A is the current first-line antimalarial
treatment in Ghana, but there has been 1 efficacy report of this regimen in Ghana till date.
Moreover, the safety of repeated treatments with ACT has been little studied. This study aims
to evaluate the efficacy of A+A vs. A-L, as well as the safety of repeated treatments of
these regimens in a longitudinal trial in which recruited children will be followed up for 1
year.
Phase:
Phase 3
Details
Lead Sponsor:
University of Ghana Medical School
Collaborator:
University of Copenhagen
Treatments:
Amodiaquine Amodiaquine, artesunate drug combination Artemether Artemether-lumefantrine combination Artemether, Lumefantrine Drug Combination Artemisinins Artesunate Lumefantrine